摘要
目的:用人源化抗人肝癌单链抗体(hscFv25)融合人突变型TNFα构建重组免疫毒素,对荷肝癌(SMMC-7721)裸鼠进行体内杀伤活性实验.方法:用纯化的hscFv25-mTNFα重组免疫毒素经尾静脉注射治疗荷肝癌裸鼠,2wk后处死裸鼠,观察肿瘤的体积、质量,并对瘤组织进行TNFα的免疫组化染色.结果:hscFv25-mTNFa治疗组对荷肝癌裸鼠的有效率为5/5,其中2/5为完全缓解,3/5为部分缓解,与mTNFa对照组相比,有显著差异(Xh2=6.62,P<0.05),疗效明显高于对照组,治疗组裸鼠的肝、肺等组织中未见转移性病灶,经hscFv25-mTNFα治疗后的瘤组织,TNFα呈弥漫性阳性反应,主要存在于瘤组织的胞质中.结论:hscFv25-mTNFa对荷肝癌裸鼠具有一定的抑瘤作用,为HCC治疗打下基础.
AIM:To explore the cytotoxic effects of humanized scFv25 and the fusion to mutant TNFα on HCC xenografts in nude mice. METHODS: The mice with HCC xenografts were injected the purified recombinant immunotoxin through tail vain and executed after two weeks. The bulk and weight of tumor were observed. Expression of TNFa was detected by immu- nohistochemical staining in the tumor tissues. RESULTS:The tumor regression trials of hscFv25-mTNFα showed 5/5 effective, with 2/5 completely remission and 3/5 partly remission. The therapeutic result of hscFv25-mTNFα was better than that of mutant TNFα (Xh2=6.62, P <0.05). The HCC tissue treated by hscFv25-mTNFα expressed TNFα, and the positive granules were mainly existed in cytoplasm. CONCLUSION:Recombinant immunotoxin the hscFV25- mTNFα can regress the growth of HCC with a great potential.
出处
《世界华人消化杂志》
CAS
2003年第3期285-288,共4页
World Chinese Journal of Digestology
基金
军队95重点补充课题
NO.98M098~~
